A STUDY BEFORE/AFTER THE IMPLEMENTATION OF AN ANTI-INFECTIOUS PRESCRIPTION AID

NCT05140213 | Completed

• 1 other identifier: RECHMPL21_0685
• Study Type: observational
• Target: 371
• Locations: 1 country
• Sites: 1

Brief Summary

Anti-infective strategy is a major public health problem. This is a before-and-after study of an anti-infectious prescription tool with a comparison of mortality at 30 days (then 3 and 6 months) between the two inclusion phases of 6 months each.

Conditions

Sepsis; Septic Shock

Keywords

Adult patients; Probabilistic antibiotic therapy to be initiated

Outcome Measures

Primary Outcomes (1)

• Numbers of patient 30-day mortality

  patient survival at 30 days

  30 day

Other Outcomes (2)

• Numbers of patient 90-day mortality

  90 days

• Numbers of patient 6 months mortality

  6 months

Study Arms (2)

Group 1 : Before

"Before" phase including 186 patients patients included before the implementation of the prescription support tool

Device: Anti-infectious prescription support tool

Group 2 : After

"After" phase including 185 patients patients included after the implementation of the prescription support tool

Device: Anti-infectious prescription support tool

Interventions

Anti-infectious prescription support tool DEVICE

implementation of a pocket notebook with current anti-infectious recommendations in the emergency department Patients were kept under surveillance for at least one hour before discharge. Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief.

Group 1 : Before; Group 2 : After

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Major patients with severe sepsis in the Montpellier emergency department

You may qualify if:

• Major patients
• Sepsis or septic shock
• Oral consent

You may not qualify if:

• minor patients
• death before antibiotherapy
• care limitations
• pre-hospital antibiotherapy

Sponsors & Collaborators

• University Hospital, Montpellier: lead

Study Sites (1)

Uh Montpellier

Montpellier, 34295, France

Location

MeSH Terms

Conditions

Sepsis; Shock, Septic

Condition Hierarchy (Ancestors)

Infections; Systemic Inflammatory Response Syndrome; Inflammation; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Shock

Study Officials

• Hamza GHOMRANI, MD

  University Hospital, Montpellier

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 17, 2021
• First Posted: December 1, 2021
• Study Start: December 12, 2020
• Primary Completion: August 12, 2021
• Study Completion: August 30, 2021
• Last Updated: December 23, 2021

Record last verified: 2021-11

Locations

FR (1)